Business Context and Reporting Period
Phibro Animal Health Corporation filed a Form 10-K for the fiscal year ended June 30, 2017. The request metadata references “2016 Q4,” but the filing is an annual fiscal 2017 report, not a quarterly filing. Phibro develops, manufactures and markets animal health, mineral nutrition and performance products in more than 65 countries.
The company operates through Animal Health, Mineral Nutrition and Performance Products segments. Animal Health represented approximately 65% of consolidated sales and includes medicated feed additives, nutritional specialties and vaccines.
Key Financial Metrics
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Net sales | $764.3 million | $751.5 million | Up 2% |
| Gross profit | $248.2 million | $239.0 million | Up 4% |
| Gross margin | 32.5% | 31.8% | Up 70 basis points |
| Operating income | $97.9 million | $85.7 million | Up 14% |
| Operating margin | 12.8% | 11.4% | Up 140 basis points |
| Net income | $64.6 million | $82.7 million | Down 22% |
| Diluted earnings per share | $1.61 | $2.07 | Down $0.46 |
| Adjusted EBITDA | $120.1 million | $114.1 million | Up 5% |
| Cash provided by operating activities | $98.4 million | $37.2 million | Up $61.2 million |
| Capital expenditures | $20.9 million | $36.4 million | Down $15.5 million |
Net margin was 8.5% in fiscal 2017 versus 11.0% in fiscal 2016. The decline primarily reflected the prior-year $19.6 million income-tax benefit, lower foreign-currency gains and a $2.6 million loss on debt extinguishment.
- Animal Health: Sales increased 2% to $497.7 million; Adjusted EBITDA increased 2% to $130.3 million. Nutritional specialties grew 18% and vaccines grew 25%, while MFAs and other products declined 5%.
- Mineral Nutrition: Sales increased 1% to $218.3 million; Adjusted EBITDA increased 16% to $17.4 million, aided by lower raw-material costs.
- Performance Products: Sales declined 1% to $48.2 million; Adjusted EBITDA increased to $2.1 million from $1.0 million.
Cash Flow, Debt and Liquidity
- Cash and cash equivalents were $56.1 million at June 30, 2017, compared with $33.6 million a year earlier; $55.2 million was held by international subsidiaries.
- Working capital was $198.0 million, and the current-assets-to-current-liabilities ratio was 2.81:1.
- Total debt was $313.1 million, including a $250.0 million Term A loan and $65.0 million drawn on the revolving facility. The debt facilities mature June 29, 2022.
- The revolving facility had $179.0 million available after borrowings and letters of credit. Israeli facilities provided an additional $13.6 million of availability, with no borrowings outstanding.
- Management stated that cash on hand, operating cash flow and financing arrangements should be sufficient for anticipated needs and that it expected to comply with debt covenants. This is management’s assessment, not a guarantee.
- Fiscal 2017 financing cash usage included $38.2 million of net debt reductions, $15.8 million of dividends, $3.9 million of refinancing costs and $1.3 million of contingent-consideration payments.
- Management expected fiscal 2018 capital expenditures of approximately $28.0 million, primarily for production capacity and manufacturing efficiency.
Material Changes Versus the Prior Comparable Period
- Revenue growth was modest but shifted toward higher-growth nutritional specialty and vaccine products. MFAs and other sales fell because of lower medically important antimicrobial volumes, regulatory changes, consumer preferences and weaker Brazilian economic conditions.
- Gross and operating margins improved due to volume growth, operating efficiencies, lower material costs and the absence of $2.6 million of acquisition-related cost of goods sold recorded in fiscal 2016.
- Operating cash flow improved substantially, mainly because fiscal 2016 working-capital investments in inventory and receivables did not recur at the same level.
- The company refinanced its debt in June 2017, replacing prior facilities with the Term A loan and revolver and recording a $2.6 million extinguishment loss.
- Goodwill increased by $2.9 million from a correction to the MVP acquisition purchase-price allocation. Management concluded the correction was not material to current or previously issued financial statements.
- Stockholders’ equity increased to $151.2 million from $90.5 million, primarily reflecting net income, stock-option exercises and favorable changes in accumulated other comprehensive income.
Guidance, Outlook, Commentary, Risks and Unusual Items
The filing does not provide formal revenue or earnings guidance. Management cited expected long-term industry growth, expansion in emerging markets, new products and lifecycle development, manufacturing efficiencies and capacity expansion as growth drivers.
- Fiscal 2017 included a $7.5 million insurance settlement gain, a $1.7 million pension settlement charge, $1.3 million of unsuccessful-acquisition transaction costs and a $1.0 million net gain from acquisition-related adjustments and intangible-asset impairments.
- The company recorded fourth-quarter impairment charges of approximately $0.7 million for Animal Health technology and $1.6 million for in-process research and development. Goodwill was tested and was not impaired.
- The FDA began steps in 2016 to withdraw approval of Mecadox, a carbadox product, over residue concerns. U.S. Mecadox sales were approximately $15 million in both fiscal 2017 and fiscal 2016; the FDA response timing was not predetermined.
- U.S. sales of products classified as medically important antimicrobials declined to approximately $23 million from $37 million, reflecting regulatory and market pressures. Total antibacterial and related-product sales were approximately $321 million, or 42% of fiscal 2017 net sales.
- Environmental liabilities accrued were $7.2 million, and letters of credit and surety bonds provided $10.0 million of financial assurance. The company is involved in the Omega Chemical Superfund groundwater matter but stated that ultimate liability cannot currently be estimated with certainty.
- Material weaknesses in internal control over financial reporting continued. The weaknesses involve transaction processing and reporting controls, system access and segregation of duties. Disclosure controls were therefore deemed ineffective, and remediation timing and success were uncertain.
- Substantially all outstanding debt was floating-rate at year-end; a 100-basis-point increase in LIBOR was estimated to increase annual interest expense by approximately $3.2 million. A $150 million interest-rate swap was entered into in July 2017.
- Additional risks include antibiotic restrictions, product liability, regulatory approvals, competition and generics, raw-material volatility, foreign exchange, dependence on Israeli and Brazilian operations, manufacturing disruptions, environmental obligations and debt covenants.
Most Important Facts for Investors to Verify
- Reconcile the requested “2016 Q4” period with the filing’s actual fiscal-year period ended June 30, 2017.
- Review the sustainability of sales and margins after the decline in MFAs and other products, particularly medically important antimicrobials.
- Track FDA action on Mecadox and quantify potential revenue and earnings exposure if approval is withdrawn.
- Assess debt-service capacity, covenant headroom, floating-rate exposure and the June 2022 maturity profile.
- Evaluate whether the $7.5 million insurance gain and other unusual items distort comparisons of recurring earnings.
- Monitor remediation of the two material weaknesses in internal controls and whether future filings report effective controls.
- Review environmental reserves and potential exposure from the Omega Chemical Superfund matter, for which the filing provides no clear ultimate-loss estimate.
- Confirm execution of planned fiscal 2018 capital expenditures, capacity expansion and the expected contribution from nutritional specialties and vaccines.